Catalent (NYSE:CTLT) Announces Earnings Results, Misses Estimates By $0.18 EPS

Catalent (NYSE:CTLT) released its quarterly earnings results on Tuesday. The company reported ($0.13) EPS for the quarter, missing analysts’ consensus estimates of $0.05 by ($0.18), Briefing.com reports. The business had revenue of $1.02 billion for the quarter, compared to analyst estimates of $1.06 billion. Catalent had a negative return on equity of 0.56% and a negative net margin of 22.72%. The company’s revenue for the quarter was up 4.2% compared to the same quarter last year. During the same period in the prior year, the business earned ($0.10) EPS.

Catalent Price Performance

Catalent stock traded down $0.24 during midday trading on Friday, reaching $59.68. 390,595 shares of the stock traded hands, compared to its average volume of 2,042,113. The stock’s fifty day moving average is $60.01 and its 200-day moving average is $58.05. Catalent has a 12 month low of $32.38 and a 12 month high of $61.20. The stock has a market cap of $10.83 billion, a P/E ratio of -10.91, a PEG ratio of 2.06 and a beta of 1.16. The company has a quick ratio of 1.96, a current ratio of 2.52 and a debt-to-equity ratio of 1.35.

Insiders Place Their Bets

In other news, insider David Mcerlane sold 1,994 shares of the business’s stock in a transaction on Thursday, September 26th. The stock was sold at an average price of $59.97, for a total value of $119,580.18. Following the completion of the transaction, the insider now directly owns 36,304 shares of the company’s stock, valued at approximately $2,177,150.88. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. 0.31% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

Several research analysts have recently commented on CTLT shares. William Blair reiterated a “market perform” rating on shares of Catalent in a research note on Tuesday, September 3rd. StockNews.com lowered shares of Catalent from a “hold” rating to a “sell” rating in a research report on Wednesday. Robert W. Baird reaffirmed a “neutral” rating and set a $63.50 target price on shares of Catalent in a research report on Tuesday, September 24th. Royal Bank of Canada reaffirmed a “sector perform” rating and issued a $63.50 price target on shares of Catalent in a research note on Thursday, July 11th. Finally, Baird R W downgraded shares of Catalent from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, September 24th. One investment analyst has rated the stock with a sell rating and eight have assigned a hold rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $59.83.

Catalent Company Profile

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.